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Abstract 
 Human African Trypanosomiasis (HAT) is one of 17 neglected tropical disease prioritized 
by the World Health Organization (WHO). Neglected tropical diseases are diseases which affect 
poor or developing countries and which do not get as much as attention as the ‘big three’: 
malaria, tuberculosis and HIV/AIDS. HAT specifically affects coutries in Sub-Saharan Africa and is 
caused by a parasitic protozoa, Trypanosoma brucei. There are two stages of HAT: the early 
haemolymphatic and late meningo-encephalitic stages. There are also two subtypes of the 
disease caused by either T. b. gambiense or T.b rhodesiense forms of the parasite. There are 
four drugs currently used to treat HAT, depending on the subtype of disease and whichever 
stage a patient is in. The nitroheterocyclic drug, Fexinidazole is currently in clinical trials for the 
treatment of both the early and late stages of HAT as well as the two subtypes. However, as 
with most antiparasitic drugs, potential parasitic resistance of the target parasite to 
Fexinidazole is an issue which must be taken into consideration and dealt with. Combination 
therapy is a method by which the likelihood of potential parasite resistance is reduced. The 
therapy uses two chemically unrelated drugs to treat a disease and is based on the theory that 
parasitic resistance to a combination therapy is less likely than resistance to a monotherapy. 
The combined drugs usually work additively or synergistically to treat the disease as well. 
Eflornithine (also known as α-difluoromethylorntihine or DFMO) is a drug currently used in 
combination with nifurtimox to treat the second stage of HAT caused by T.b gambiense. 
Nifurtimox and Fexinidazole are both nitroheterocyclic drugs and as a result, have similar modes 
of action. Therefore, I believe that eflornithine is the ideal partner drug to be used in conjunction 
with Fexinidazole since it has been shown to be effective in combination with a Fexinidazole-
related drug (nifurtimox) but is not chemically related to Fexinidazole. The use of this 
combination therapy will allow prolonged use of Fexinidazole in treating HAT and contribute 
towards the eventual elimination of the disease. 
 
Keywords: Human African Trypanosomiasis (HAT), sleeping sickness, haemolymphatic, 
meningoencephalitic, Trypanosoma brucei gambiense, Trypanosoma brucei rhodesiense, eflornithine, 
fexinidazole, combination therapy, monotherapy  
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Introduction 
Human African Trypanosomiasis (HAT) 
 Human African Trypanosomiasis (HAT) is a 
neglected tropical disease which is communicable 
and prevails in tropical climates. The disease, also 
known as sleeping sickness, is caused by the 
parasitic protist Trypanosoma brucei and is 
transmitted from host to host by the tsetse fly 
(Glossina sp.)(1). The reason for the disease’s 
restriction to tropical climates is due to its vector, 
the tsetse fly, being prevalent only in such 
climates. The fly is specifically restricted to areas 
between the latitudes of 14˚N and 20˚S. as these 
areas have temperatures between 16°C–38°C and relative humidity levels of 50%-80%; 
temperatures ideal for tsetse fly survival(2). As a result, HAT is endemic to thirty-six countries in 
sub-saharan African countries which fall within the above-mentioned latitudes (shown in fig. 
1)(3)4). These countries cover an area of 9 million km2 leaving an estimated 60 million out of 
the 400 million inhabitants of these areas at risk of contracting the disease(4,5).  
Neglected Tropical Diseases 
Figure 1.  Prevalence and incidence of HAT in sub-Saharan African 
countries as recorded by WHO in 2013 (3). 
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Most diseases, such as HAT, which affect the poor and vulnerable in underdeveloped or 
developing countries have been grouped together under the title, “Neglected Tropical 
Diseases” (NTDs)(6). NTDs are different from the three major diseases- HIV/AIDS, tuberculosis 
and malaria- which receive a great deal of attention and funding though these three also affect 
developing countries(6–8). However, this does not mean that NTDs are completely ignored by 
the world. As a matter of fact, one-half of the 2015 Nobel Prize in Medicine was awarded to 
scientists William C. Campbell and Satoshi Omura for their work in developing avermectin, a 
novel therapy against onchocerciasis and lymphatic filariasis which are both caused by 
roundworm parasites and are both NTDs(9–11). The other half of the prize was awarded to 
Youyou Tu for discovering a new therapy against malaria(10). The awarding of the prize to the 
above-mentioned diseases, especially onchocerciasis, marked a milestone in infectious diseases 
affecting poor countries. The World Health Organization (WHO) has prioritized seventeen of 
these diseases, including HAT, which are caused by four major types of pathogens: protozoa, 
helminths, viruses and fungi(12). The diseases are all communicable and their causative 
Figure 2. Countries affected by the NTDS. Some counties are affected by more than one NTD (8). 
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pathogens thrive in tropical and sub-tropical climates, hence why they do not prevail in other 
countries but only prevail in the countries they do (as seen in fig. 2).  
Together the seventeen NTDs affect more than a hundred countries and 1.4 billion 
people which is approximately one-sixth of the world’s population. In terms of mortality, the 
diseases cause the deaths of up to 500,000 people annually. The reason why the diseases thrive 
in poor areas is due to the fact that these areas suffer from inadequate access to clean water, 
poor nutrition, and poor hygiene amongst other less than optimal living conditions which are 
ideal for communicable diseases(13). In addition, the diseases leave those who are infected 
unable to work and earn a living due to cognitive and physical impairment. As a result, NTD 
infections result in a vicious cycle of poverty in infected communities where they are both its 
cause and effect(6). Although these diseases are termed “neglected,” commitment to 
controlling the various NTDs have increased internationally in recent years(7). In fact, in the 
year 2012, WHO formulated a “Roadmap” towards the control and the elimination of NTDs(7). 
For some diseases, the strategy for control was through preventive chemotherapy. For other 
diseases, such as Human African Trypanosomiasis (HAT), prophylactic treatment is not used; 
instead, the method of control is based on detection of the cases along with intensified disease 
management (IDM)(7). In this thesis, a literature review of the efforts that have been taken to 
control HAT so far will be provided. However, this cannot be done without some background 
information about the disease, something that will be discussed as well. In addition, a proposal 
will be made for the potential improvement of HAT treatment, especially if WHO’s plan target 
for the elimination of HAT by 2020 is to be achieved(7). 
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HAT History 
Sleeping sickness was first associated with the slave trade in early modern times as the 
earliest accounts of the disease at that time were written by slave trade companies’ ship 
doctors and medical officers(14). The first accurate medical report of HAT was published in 
1734 by an English naval surgeon named John Atkins. However, despite increasing reports of 
sleeping sickness in the nineteenth century, details about it were not known. It was not till the 
year 1852 that sleeping sickness was associated with the bite of a tsetse fly. This relationship 
was discovered by David Livingston, a Scottish missionary and explorer. Although it was now 
known how the disease was transmitted, the actual causative agent was still unknown. 
Trypanosomes were not identified as the parasites responsible for HAT until 40-50 years after 
the discovery of its vector was made. Scottish pathologist and microbiologist, David Bruce 
discovered the protist, Trypanosoma brucei as the agent of infection in cattle trypanosomiasis 
(also known as cattle nagana) in 1895. Definitive identification of the trypanosoma parasite as 
the cause of HAT occurred when the protist was observed in the blood of an infected human in 
by a British Colonial surgeon in 1901. The following year, the parasite was also observed in the 
cerebrospinal fluid of infected patients.  
 There have been three major epidemics of Human African Trypanosomiasis that have 
been recorded and they all happened in the twentieth century(14,15). The first one was a 
severe epidemic that caused the deaths of between 300,000-500,000 people. It began in 1896 
and did not end until 1906. It affected mainly Congo and Uganda, but also Kenya. This epidemic 
occurred during colonial times and it curbed the development of colonial territories(5). This 
first epidemic also began before any information had been gathered about sleeping sickness. 
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Therefore, all the discoveries concerning HAT which were described above happened as a result 
of the colonial administration’s attempts to prevent the disease from dismantling their colonies 
and leaving them without laborers(5,14). Once the disease had been clearly identified, along 
with its causative agent, control measures were established to stop the HAT epidemic.  
 The second major HAT epidemic began in 1920 and did not die down until the 1940s. 
The discovery of two drugs for treating HAT, suramin, which is still used today, and 
tryparsamide, an organo-arsenical drug, contributed greatly to the fight against the second 
epidemic. Other additional measures such as the introduction of mobile teams were 
undertaken to control the spread of the disease. With the mobile teams, systematic detection 
and treatment of infected people was initiated. Other measures which were also introduced 
and contributed to the control of the epidemic, including vector control and host reservoir 
control(14). 
The discovery of more drugs against HAT such as melarsoprol and pentamidine along 
with the combination of the systematic case screening and vector control eventually led to a 
dramatic decrease in HAT incidence once the 1960s began(14). In fact, HAT transmission in 
endemic areas was disrupted at this time so much that interest was lost in the disease(5). A loss 
of interest in the diseases resulted in discontinued surveillance and the risk of re-emergence of 
the disease was not taken into consideration(5). Discontinued surveillance was encouraged by 
HAT-endemic countries gaining their independence from the colonial powers in the 1960s. This 
led to both political and economic instability as the nations tried to determine how to stand on 
their own feet. The economic instability also negatively impacted the healthcare infrastructure 
in these countries so that HAT surveillance and control was no longer a priority(14).  
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The combination of reduced awareness of HAT, diminished HAT priority, and social 
instability and conflicts made it difficult for control interventions, resulting in a re-emergence of 
the disease in epidemic proportions(2). This constituted the third major HAT epidemic, lasting 
from the 1980s to the 1990s. The only countries which were affected were Angola, the 
Democratic Republic of the Congo, Southern Sudan, and the West Nile district of Uganda; but, 
only a fraction of these areas were under surveillance(2,14). An estimated 30,000 cases were 
reported annually during this time. However, due to the fact that civil wars and social upheaval 
prevented access to a large number of the affected populations, WHO estimated that the 
number of people affected was more likely 10 times more than the reported number of 
cases(5).  As a result, WHO improved its coordinating abilities and began to advocate and raise 
awareness of the disease so that both the public and private sectors contributed resources for 
HAT control and surveillance(2,5).  
Eventually, all the above-metioned efforts began to yield results; the number of HAT 
cases began to decrease steadily, falling below 10,000 since 2009. Figure 3 below shows the rise 
and fall in the incidence of cases, including during the period when HAT reached epidemic 
proportions. Although global incidence of HAT is low and seems to be declining, it is important 
to note that there are still areas in Sub-Saharan Africa where it remains a “hidden epidemic” 
under continuous surveillance(2,16). Therefore, the disease should not be written off as a 
public concern as this would be  premature(16). Additionally, history has shown that HAT 
incidence is characterized by epidemics that occur in episodes and resurgences, indicating the 
importance of maintaining HAT control methods(17). 
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Figure 1. Recorded number of HAT cases from 1940 to 2012 (10) 
 
HAT pathogen 
 Sleeping sickness, as mentioned before, is caused by Trypanosoma brucei, a unicellular, 
flagellated protozoan parasite (seen in fig. 
4). The flagella helps to move the parasite in 
whichever direction it elongates its 
body(16). With the flagella, the 
trypanosome is able to travel at speeds up 
to 20 um s-1, making it a highly motile 
cell(18)  There are two subspecies of T. 
brucei which infect humans, T.b gambiense 
and T.b rhodesiense(19). The gambiense form of the disease is known to be the causative agent 
of HAT in West and Central Africa while the rhodesiense form infects the eastern part of 
Figure 2. Scanning Electron Micrograph (SEM) of T.brucei (16) 
T o m a  | 8 
 
Africa(20). The gambiense form is also more chronic, lasting up to three years and accounting 
for approximately 98% of observed HAT cases(20).  This subtype of HAT is anthroponotic, 
meaning it primarily affects humans but can also be transferred to animals(2,21). It is 
transferred from host to host by riverine tsetse flies, Glossina palpalis (22,23).  
Conversely, the rhodesiense form of HAT is a more acute and progressive type of the 
disease, lasting only months rather than years(2). This is the main difference between both 
forms of the disease. Another difference between the two is that the rhodensiense form, unlike 
the gambiense one, is a zoonotic disease(22). Its transmission cycle happens mainly between 
wild and domestic animals but can also intensify to human infection(2,20).  The tsetse flies 
responsible for transmission of this subtype of T.brucei are the Savannah flies (Glossina 
morsitans)  (22,23). The rhodesiense form of HAT accounts for the other 2% of observed HAT 
cases(2).  
There is a third subtype of T.brucei, T.b brucei. Unlike the other subtypes, this one does 
not infect humans but is only infectious to wild and domestic animals(14,24). This subtype is 
commonly used in the models for experiments dealing with HAT(2). T.b. brucei, like the other 
subtypes, is also transmitted by the tsetse fly. The three subtypes are morphologically 
indistinguishable from each other and also have similar life cycles(25).  
T. brucei life cycle in the tsetse fly 
 Despite the fact that HAT is highly life-threatening, the causative pathogen cannot infect 
a new host if it is not done through the bite of a tsetse fly (Glossina spp.)(16). However, the 
environment encountered by T. brucei during mammalian infection differs from the 
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environment in the tsetse fly vector(17).  Therefore, in order for the unicellular eukaryote to 
survive and proliferate, it must adapt by undergoing developmental changes throughout its life 
cycle in the different environments(25,26). These developmental transformations include 
changes in cell length and width, length of the flagella, and the relative position of the 
nucleus(16). As a result, the changes result in the formation of different T.brucei forms with 
morphological differences(26).  
Tsetse flies are blood-feeding insects 
which obtain energy and nutrients solely from 
the blood that they feed upon(27). As a result, 
they are referred to as hematophagous 
arthropods(28). The insects pick-up the T. brucei 
parasite when they feed on the blood of an 
infected host(29,30). A picture of the tsetse flying biting a mammal is shown in fig. 5. The life 
cycle of the parasite while is in the insect is known as the procyclic stage(31). The tsetse fly 
ingests T.brucei (into its midgut) from the bloodstream of the infected mammal while it is in its 
trypomastigote form. Two types of the bloodstream form (BSF) trypomastigotes are ingested by 
the fly during blood-feeding: the short stumpy (ST) form which cannot divide and the long 
slender (LS) form(16,32,33). Therefore, once in the insect’s midgut, ST trypomastigotes 
transform into procyclic trypomastigotes which are able to proliferate in the tsete fly’s midgut, 
thereby, allowing for infection of the fly(34). LS trypomastigotes, however, are unable to 
transform and therefore, die out(16). It is thought that the ST forms are pre-adapted to the 
environment in the midgut which is why they are able to differentiate, unlike the LS 
Figure 5. A tsetse fly feeding on blood by puncturing the 
skin of a human (23). 
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forms(32,35). Figure 6 shows scanning electon micrographs 
of the BSF versus the procyclic form of T. brucei(17).  
The procyclic form of the trypanosome is only 
infective of the tsetse fly and cannot infect mammals but 
must first develop through a series of transformations 
(which will be discussed shortly) before it can do 
so(18,36,37). Once differentiation into the procyclic form of 
the trypanosome has occurred, multiplication of the cell 
begins(20).  Infection of the fly’s midgut is not always 
successful as immunity-related factors subject proliferation to a 
series of bottlenecks(16). Infection is deemed successful if trypanosomes are found in the 
ectoperitrophic space (part of the midgut) three days post-infection as differentiation and 
proliferation lasts two to three days(16).  After the infection of the tsetse fly has been 
established, the parasites then travel towards the anterior end of its alimentary canal (or 
midgut) to the proventriculus (PV). This journey is accompanied by elongation of the procyclic 
trypomastigotes into mesocyclic trypomastigotes(16,20). The mesocyclic trypomastigotes have 
longer flagella which help to enhance migration of the cells(16). Once the mesocyclic cells arrive 
at the proventriculus, they proceed to transform into the thinner and longer epimastigote 
forms of the T.brucei cell(20).  Asymmetrical division of the epimastigotes occurs after the 
transformation which results in long and short epimastigotes. The long epimastigotes have 
more motility than their short counterparts and so serve as transport vehicles for them as they 
travel towards the salivary gland of the fly(16,20). Movement from the proventriculus to the 
Figure 6.  SEM of bloodstream form 
(BSF) and procyclic form (PCF) of the 
African trypanosome (17). 
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salivary gland is done via the fly’s foregut and proboscis, meaning only a small number of 
parasites are able to complete the journey(20). Therefore, the migration process serves as 
another bottleneck for T.brucei parasites in the tsetse fly(16). The cells that are able to 
circumvent this bottleneck then attach to the epithelium of the salivary glands via their 
flagella(16). After attachment, the epimastigotes, like the procyclic trypomastigotes, begin to 
proliferate.  
Colonization of the tsetse fly’s salivary glands is achieved through normal cell division of 
the trypanosome. This is eventually followed by another round of asymmetrical division which 
results in the formation of a daughter cell that matures into a metacyclic form of the parasitic 
eukaryote. This metacyclic form is non-dividing and primed to adapt to or survive the 
environment in the mammalian host(34). Therefore, it is an infective form which can then be 
injected by the tsetse fly into a new host during feeding, thereby infecting it(16,30). However, 
maturation of the metacyclic trypomastigote is not complete until the cell acquired its variant 
surface glycoprotein (VSG) coat(18). It is the VSG-coated metacyclic trypanosomes that are 
ultimately released through the tsetse fly’s saliva(18).  Genetic exchange, the mating of T.brucei 
cells, is said to happen in the salivary glands of the fly(24,38). The entire process, from ingestion 
of the BSF trypomastigotes to maturation of the metacyclic trypomastigotes takes about twenty 
to thirty days in the tsetse fly(36). This ability of the tsetse fly to acquire the trypanosomal 
parasite, allow it to mature and finally transmit to a new mammalian host is described as vector 
competence(37). A summary of the life cycle of the trypanosome in the tsetse fly is shown in 
figure 7 below(16).  
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Figure 3. Life cycle of T.brucei in the tsetse fly. (I)The fly ingests the long slender (LS) and short stumpy (ST) trypomastigote forms 
which are then present in its midgut. The ST forms differentiate into the procyclic trypomastigote forms which are proliferative 
in nature (II). After infection is established, the PC trypomastigotes migrate toward the anterior portion of the midgut, 
elongating into mesocyclic trypomastigotes (MS), which are found in the foregut (FG), in the process (III). Once the MS forms 
arrive at the proventriculus (PV), they differentiate into epimastigotes which then divide (DE) asymmetrically into long and short 
epimastigotes (IV). Long and short epimastigotes travel to the salivary glands and a fraction are able to attach themselves to the 
epithelium (AE). The epimastigotes then undergo normal cell division (Epi-Epi) in order to establish infection in the SG or 
asymmetrical division (Epi-Trypo) to produce infective metacyclic trypomastigotes (MT) (VI (16)).  
 
Life cycle of T. brucei in mammalian hosts 
 In mammalian hosts, infection is initiated when an infected tsetse fly deposits 
metacyclic trypomastigotes in the connective tissue of the host’s dermal layer(28). Once it is 
deposited, the parasite proliferates at the site of inoculation before migrating to the lymph and 
blood circulation circuits(3). This is known as the early haemolymphatic stage of infection(18). 
Although it may cross through the walls of the lymphatic and blood capillaries into connective 
tissue, the parasite always remains extracellular(28). Eventually, the protozoan cells cross into 
the central nervous system (CNS) and cerebrospinal fluid by crossing the blood-brain barrier 
(BBB) or blood-CSF barrier(28). This is referred to as the late, meningo-encephalitic stage of 
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T.brucei infection(18). HAT is always fatal if left untreated due to this ability of the parasite to 
invade the CNS(18). The migration of the parasitic cells into the CNS provides a privileged 
environment which is not easily accessible by chemotherapy. Therefore, the CNS can serve as a 
reservoir, allowing T.brucei cells to re-infect the host(18).  
Unlike its life cycle in the tsetse fly, during which the trypanosome is characterized by 
different forms, the lifecycle of the protozoan in its mammalian host consists mainly of two 
forms: long slender (LS) and short stumpy (ST) form of trypomastigotes(28). The two 
trypomastigote forms are easily distinguishable from each other under the microscope(26).The 
LS form is the dividing form while the ST form is irreversibly arrested in the cell cycle making it 
non-proliferative(25,39). The ST trypomastigote, however, is adapted for transmission into the 
tsetse fly as mentioned before(33,40). T.brucei also has transitional forms between the LS and 
ST trypomastigote forms. These forms are referred to as intermediate forms(32).  
Transformation of the parasitic eukaryote from LS into ST forms occurs when parasite 
numbers increase in the host(41). The reason for this transformation is to maintain proliferation 
at sub-lethal levels in the host. In this way, the parasites avoid killing the host, as this would 
result in their death as well(39). Therefore, a balance always exists between the host and the 
parasite. T.brucei levels must be obtained at levels high enough for chronic infection to occur 
but must not be high enough to overwhelm the host before transmission occurs as this would 
lead to its extinction(39). The LS trypomastigotes have a density-sensing mechanism which 
allows them to detect when parasitic levels are getting lethal. This causes the arrest of some LS 
forms in a certain stage of the cell cycle (the G0/G1 stage), forming ST trypomastigotes which 
have a lifespan of abo two to three days after the cell cycle arrest(39). In this way, host survival 
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is prolonged and transmission is also ready to be carried out(32). As a result, parasitemia in the 
host is marked by cyclical waves of rising and decreasing levels of infection (36) (shown in fig. 
8).  
 
Figure 4. Once a mammalian host is infected, long slender trypomastigotes begin to proliferate leading to rising parasitemic 
levels. Through density-sensing mechanisms, the LS form is able to perceive when parasitemic levels are getting too high i.e 
becoming lethal to the host mammal. Once this happens LS forms exit the cell cycle at the G0/G1 stage, forming short stumpy 
(ST) trypomastigotes. ST forms have a short lifespan and are non-proliferative in nature. Therefore, transformation into ST forms 
promotes host survival and decreased parasitemic levels. It is also at this point, that transmission of the parasite into the tsetse 
fly occurs. Once parasitemic levels decrease in the host, LS forms which did not exit the cell cycle begin proliferating again, 
starting the parasitemic wave over again (42). 
 
The VSG coat and antigenic variation 
As previously mentioned, T.brucei remains extracellular throughout its infection of a 
mammalian host. As a result, the parasite is left constantly exposed and vulnerable to the 
immune system of the host(42). Despite this, it is still able to establish prolonged infection in 
the host, resulting in a variety of pathological manifestations(43). The trypanosome is able to 
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do so because its surface is completely covered by a homogenous protein coat known as the 
variant surface glycoprotein coat (VSG)(30). This coat is comprised of approximately 107 densely 
packed molecules of a single VSG type and is responsible for determining the phenotype of the 
parasite’s antigens(44).  
The dense VSG coat shields the non-changing antigens on the surface of the protozoan 
parasite, preventing them from being detected or accessed by the adaptive immunity of the 
host(42,43). The VSG coat is also responsible for preventing T.brucei from activating the 
alternative complement pathway in the host(30). Despite this, the host’s immune system is still 
able to produce antibodies against the VSG, eventually resulting in lysis of the parasitic cells. In 
order to circumvent this and continue to survive, T. brucei periodically switches to an 
immunologically different VSG(42). This ability of the trypanosome to change the identity of the 
VSG type comprising its glycoprotein coat is referred to as antigenic variation(42). The 
trypanosome has up to 2000 genes responsible for the expression of the VSG types. In addition, 
genetic recombination of these genes also account for distinct VSG types. The parasite 
possesses mechanisms which ensure that only one VSG gene is transcribed at a time(28). As a 
result, the trypanosome has an almost inexhaustible repertoire of antigens that can be 
expressed on its coat(44,45).  Experimentally, a single trypanosome was observed to express at 
least 100 distinct VSG coats. However, this is an underestimation due to limited ability to detect 
the varying VSG types(30). 
 Antigenic variation is one of the most remarkable mechanisms of adaptation that the 
African trypanosome exhibits(28). It is also the most important contributing factor to the 
parasite’s ability to evade the host’s immune system and establish chronic infection(28,44).  
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During trypanosomal infection, a few parasites switch their VSG type at random(39,45). 
Therefore, when the immune system recognizes and clears parasites exhibiting the previous 
VSG variant, the parasites with the new variant survive. It is usually the short stumpy (ST) 
trypomastigote forms that are the survivors as they are more resistant to antibody-dependent 
complement-mediated cell clearance than their long slender counterparts(46). These survivors 
eventually give rise to a peak in parasitemic levels which is again decimated when antibodies 
are produced against those variants(42). As a result, infection of the host is characterized by 
cyclical waves of parasitemia (seen in fig. 9)(36,42,45). This eventually results in exhaustion of 
the host’s immune system(28). The ability of the trypanosome to undergo antigenic variation 
has been a major obstacle in vaccine development against HAT and has made prophylactic 
treatment an unlikely option in HAT control(47,48). This is evidenced by the fact that no vaccine 
trial with promising results has led to positive field trials(49). 
 
 
Figure 5. Parasitemic levels observed in a T. brucei- infected cow showing cyclical waves of parasitemia(43)  
 
The VSG coat is only found on the bloodstream form (BSF)  long slender and short 
stumpy trypomastigotes. When the BSF trypomastigotes differentiate into the procyclic 
trypomastigote in the midgut of the tsetse fly, they shed the dense VSG coat and replace it with 
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a procyclin coat(25,41). As a result, if the parasite were ever to transform into its procyclic form 
within the mammalian host, it would be rapidly cleared by the immune system as it does not 
have sufficient protection. Considering this information, induction of premature transformation 
of T.brucei into its procyclic form while in the mammalian host could serve as a potential 
chemotherapeutic approach for treating HAT(25).  
Clinical presentation: signs, symptoms and diagnosis 
 It was mentioned previously that during HAT infection, the T.brucei parasite progresses 
through two stages of infection. The first and early stage is referred to as the haemolymphatic 
stage. It is the stage of infection during which the parasite is restricted to and proliferates in the 
blood and lymph of the host(50). Eventually, the parasite invades the CNS by crossing the 
blood-brain barrier (BBB) or blood-csf barrier (BCB)(51). This constitutes the second or late 
stage of HAT infection, also referred to as the meningo-encephalitic stage(52,53). Infection 
always progresses from the first stage to the second stage if left untreated as the stages are 
sequential in nature(52).  
The progression of HAT from the early to the late stages is characteristic of infection by 
either of the two T.brucei subtypes, T.b. rhodesiense and T.b. gambiense(3).  However, as 
discussed previously, rhodesiense infection is the more acute form of HAT, lasting only 
months(54). On the other hand, HAT caused by the gambiense form presents with a more 
chronic form, lasting years(1,3).  As a result, invasion of the CNS, progression to the second 
stage of infection, occurs after about 3 weeks in rhodesiense HAT infection and after about a 
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year in gambiense HAT(55,56). This constitutes the main difference between the two HAT 
infection subtypes.  
 HAT infection by the rhodesiense subtype of the trypanosome is marked by a chancre in 
5-26% of infected patients(1,50). The chancre 
develops as a result of an inflammatory response to 
the inoculation of T.b rhodesiense parasites into the 
patient through the bite of the tsetse fly. The chancre 
marks the area where the patient was bitten by the 
fly and is the first sign of disease in these cases(1,50). 
The chancre is characterized by local redness, 
swelling, heat, and tenderness (as seen in fig. 10) at 
the site of the bite(1).  The chancre is rarely seen in patients infected with the gambiense form 
of HAT.  
 Due to the differences in infected areas between the two stages of sleeping sickness, 
they present differently in clinical situations. The early stage of HAT presents with non-specific 
symptoms such as intermittent fever, headaches, severe itching of the skin, skin lesions, 
weakness, anemia, lymphadenopathies, endocrine disturbances, muscoskeletal pains, cardiac 
disorders, hepatosplenomegaly, and edema of the face and the extremities(1–3). Once the 
disease progresses to the second stage, it presents clinically with features that can be 
categorized into psychiatric, motor and sensor abnormalities, and sleep disturbances(57). While 
these signs and symptoms are more specific than those of early HAT stage infection, they are 
still not individually diagnostic of HAT, as some of them characterize other CNS diseases as 
Figure 6. Chancre on the leg of a patient bitten by a 
tsetse fly and subsequently diagnosed with HAT 
infection by T.b brucei (55). 
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well(57). If left untreated, HAT is fatal to the infected patient as it progresses to systemic organ 
failure, cerebral edema, coma, and death(3,57).  
 Diagnosis of HAT is achieved using a combination of clinical and investigative data(57). If 
the set of symptoms described above present clinically in the context of a geographical location 
endemic to HAT, this would serve as an important clue for diagnosis(57). However, even in 
these endemic areas, rhodesiense HAT, for example, which is characterized by fevers of 103-
105°F(54), is often misdiagnosed as other febrile 
endemic diseases with similar clinical signs(58). 
Examples of these diseases include malaria, 
enteric fever, meningitis, tuberculosis, and 
HIV/AIDS(58). Therefore, the non-specificity of the 
disease’s signs and symptoms requires that 
diagnosis be confirmed by lab tests and 
results(52,58). A confirming lab result would be 
the detection of trypanosomes in the patient’s 
blood (seen in figure 11) or other tissues such as the lymph node during the early stage of the 
disease(57).  
Parasites are relatively easy to detect in rhodesiense HAT due to the presence of 
numerous bloodstream trypanosomes in this subtype of the infection(57,58). However, this is 
not the case in infections caused by T.b gambiense as fluctuating parasitemic levels, since cyclic 
parasitemia (as a result of antigenic variation discussed previously) is a characteristic of this 
infection subtype(57,58). Therefore, parasitological confirmation is more difficult with 
Figure 7. Colored scanning electron micrograph of 
T.brucei cells amongst human red blood cells (58) 
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gambiense HAT. This is where serological tests such as the one currently being used, card 
agglutination test for trypanosomiasis (CATT), come in. CATT is a simple and rapid direct 
agglutination assay used to detect the presence of antibodies specific to  T.b. gambiense  in the 
blood, plasma or serum of patients(59). The assay has a sensitivity rate of 87-98% and a 
specificity rate of 93-95% making it very reliable(21). CATT is used for screening purposes in the 
field, followed by parasitological confirmation(59). In other words, once a patient yields a 
positive CATT result, a microscopic search is then done for trypanosomes in the lymph nodes 
and blood(52). 
An important part of HAT diagnosis is determining which stage of infection a HAT 
patient is in as therapeutic decisions are based on this information. The haemolymphatic stage 
must be reliably distinguished from the meningo-encephalitic stage as failure to treat a patient 
with T.brucei CNS infection results in fatality. Conversesly, inappropriate treatment of an early 
stage patient for CNS infection involves high risk of unnecessary drug toxicity(57). Reliable 
staging of HAT is done by performing a lumbar puncture on the patient in order to examine the 
CSF(52,55). The criteria for CNS involvement in HAT infection is defined by WHO as the 
detection of trypanosomes in the CSF or a white blood cell count (WBC) of  >5cells/μl, or both 
(3,52,57). 
Current treatments 
 The BBB is highly selective – it prevents 98% of all known compounds from entering into 
the CNS including drugs used in treating HAT(60).  As a result, drugs used in the treatment of 
late stage sleeping sickness are toxic in their own right and differ from those used in treating 
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the early stages(3,60). The chemotherapeutic agent used in treating HAT also depends on which 
subtype of the parasite is the causative agent of infection as different drugs are used to treat 
the different HAT subtypes(3).  
 First stage sleeping sickness is treated with suramin in rhodesiense infection and 
pentamidine in the gambiense subtype(61). Suramin is a trypanocidal drug which is a derivative 
of a naphthalene urea compound 
(seen in fig. 12)(62). The drug is 
administered intravenously over the 
course of thirty days with a complex 
dose regimen(1,50). It is associated 
with complications such as renal 
failure, skin lesions, nephrotoxicity bone marrow toxicity, and peripheral neuropathy(1,50). 
However, these side effects are usually mild and reversible(1). Anaphylactic shock is another 
side effect of suramin treatment when acute hypersensitivity reactions occur. As a result, a low 
test dose is usually applied to the patient before the beginning of treatment(1). 
 Pentamidine, an aromatic diamidine (seen in fig. 13), has been in use for the treatment 
of HAT infection since the 
1930s(15). The drug was originally 
used with the intention of starving 
bloodstream trypanosomes of 
glucose; however, it was later 
discovered that it was trypanocidal in its own right(15). It is administered once daily over the 
Figure 8. Chemical structure of suramin, a naphthalene urea derivative. It 
was previously called Bayer 205 and Germanin before being renamed 
suramin (63) 
Figure 9. Chemical structure of pentamidine, an aromatic diamidine used in 
treating HAT stage 1 (63) 
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course of seven days though intramuscular means(3,15). The side effects of pentamidine 
treatment include nausea and vomiting, hypoglycemia, and pain at the site of injection(1,3). 
Despite this, the drug is generally well-tolerated(3). Treatment has proven to be effective and 
able to prevent the progression of disease(57). 
The treatments used in combatting second stage HAT are melarsoprol, eflornithine, and 
a combination therapy of eflornithine and nifurtimox (NECT)(3). Melarsoprol is a trivalent 
organic arsenical compound (seen in fig. 14) that was first discovered to treat second stage HAT 
in 1949(61). Its mechanism of action is not 
known(52). However, the drug was found to 
be effective in treating both the gambiense 
and rhodesiense forms of sleeping sickness 
and was the only available drug for treating 
both for fifty years after it was first 
discovered(1). Its administration involves 
three to four doses daily over the course of three to four weeks followed by clinical evaluation 
every six months during the next two years for follow-up purposes(57). This treatment course 
has been shortened to daily injections of the drug for ten consecutive days(1,61). However, 
melarsoprol as an arsenic-based drug is toxic and is known to cause reactive encephalopathy in 
about 10% of treated patients(50). Reactive encephalopathy is characterized by coma and 
repeated convulsions which result in the death of 50% of these patients(52). Due to the toxicity 
and side effects of melarsoprol, a search was undertaken to find an alternative treatment for 
late stage HAT infection. Melarsoprol has a high efficacy rate in HAT patients but has been 
Figure 10. Chemical structure of melarsoprol- an arsenic-based 
drug usind in treating late stage HAT (63) 
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observed to have a failure rate of about 30%(57). This treatment failure is possibly caused by 
drug resistance in trypanosome cells(15). 
Eventually, in the mid-1980s, eflornithine (α-difluoromethylorntihine or DFMO seen in 
fig. 15) was found as an alternative 
treatment and safer treatment for late stage 
sleeping sickness(52) In 2000, twenty years 
after its efficacy was first established, it was 
made available for clinical use(1). The drug 
functions by affecting the synthesis of 
polyamines - important organic compounds required for growth and multiplication by all 
eukaryotic cells - in trypanosomal cells(52). Specifically, eflonithine irreversibly inihibits 
trypanosomal ornithine decarboxylase (ODC), an enzyme involved in the metabolic pathway. 
 Eflornithine chemotherapy involves the administration of fifty-six intravenous injections 
of the drug over the course of fourteen days: 100mg/kg two hour infusions four times 
daily(52,63). Once it was made available for clinical use, eflornithine was made the first-line 
treatment for treatment of gambiense HAT(1,52). However, its use is constrained by the fact 
that its administration is long and burdensome and not ideal for HAT-infected areas where 
material and human resources are already limited(1,63). To mitigate some of these difficulties, 
WHO provided kits with the necessary supporting materials for treatment and coordinated 
training of personnel from national sleeping sickness control programs(1,52). The WHO made 
these efforts in 2006. Following this, eflornithine use as first-line treatment for gambiense 
sleeping sickness began to increase(52).  
Figure 11. Chemical structure of eflornithine (63) 
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NIfurtimox is a nitrofuran derivative 
organic compound (seen in fig.16). The drug is 
used to treat Chagas disease caused by 
Trypanosoma cruzi but was found to work as a 
partner drug with eflornithine in a combination 
therapy(52,62). Nifurtimox and eflornithine 
combination therapy (NECT) was implemented 
in the treatment of sleeping sickness in an effort to shorten and simplify eflornithine 
monotherapy(1). The combination therapy was discovered to be less cumbersome and difficult 
to administer, requiring only fourteen intravenous injections of eflornithine over seven days 
rather than the fifty-six injections of eflornithine monotherapy over fourteen 
days(52,63).Therefore, NECT not only involves a fourfold decrease in the number of IV 
(intravenous) infusions of eflornithine needed but also a decrease in the duration of treatment. 
Nifurtimox is taken orally three times per day for the duration of ten days(63).  
NECT also involves a decrease in cost of treatment and an increase in the efficacy of 
eflornithine(3,63). Therefore, NECT has been recommended by WHO as the first-line treatment 
for late stage HAT infection by T.b gambiense. In 2009, it was added to WHO’s List of Essential 
Medicines(1,61). The addition of the combination therapy to this list was what opened the way 
for its use in HAT-affected countries(63). The discovery of the combination therapy was a 
breakthrough in HAT treatment as it was the first new registered HAT drug since 1981(57). 
However, melarsoprol still remains the only treatment for the second stage of rhodesiense 
sleeping sickness(1).  
Figure 12. Chemical structure of nifurtimox- a nitroguran 
derivative (63) 
T o m a  | 25 
 
Vector control 
 One other way through which HAT is controlled, apart from chemotherapy, is vector 
control. By controlling the vector, transmission of HAT is reduced and people are protected(64). 
One of the methods of vector control uses insecticide-treated and non-treated fly traps or 
screens which allow for a reduction in fly density in areas where it is high(1,4). Some of the 
traps are color-baited as it was discovered that the flies are drawn to blue/black 
colors(27).Other available control methods which are used include insecticide-treated cattle, 
aerial or ground spraying of low dose insecticides (such as pyrethroids) and the fogging of 
tsetse fly resting sites(21,65,66).  
Interestingly, vector control is also achieved through the introduction of sterile tsetse 
males into areas populated with the insects. This technique is referred to as SIT, sterile insect 
technique(21). The sterile males mate with the females but do not produce offspring. However, 
tsetse females can only mate once during their lifetime. Therefore, they themselves are 
practically rendered sterile as well and no new tsetse flies are produced(21,23). Considering 
that rhodesiense HAT is zoonotic in nature, control of the animal reservoir is the main 
challenge. For example, cattle are known to be major reservoirs of the disease(67). However, 
cattle can be treated with insecticides (a cost-effective method of vector control), but control of 
the disease and vector in wildlife living in game parks and protected areas is difficult(1). In the 
absence of prophylactic treatments against sleeping sickness, vector control is very important 
and research continues to be done to improve control techniques(64). 
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Fexinidazole 
 The harmful side effects of current HAT treatments, especially melarsoprol, the only 
treatment for late stage HAT, along with the report of treatment failures led to the search for 
new drugs against HAT(68). Research was performed to find not only new HAT drugs but also 
effective and safer ones as well(3). The newly discovered drug would also be ideal if it could 
treat both the haemolymphatic and meningo-encephalitic stages of sleeping sickness as this 
would preclude staging of the disease and its associated difficulties(57).  
Fexinidazole (1H-imidazole,1-methyl-2-[{4-
methylthio} phenoxy] methyl] 5-nitroimidazole), a 2-
substituted 5-imidazole organic compound, is a HAT drug 
that is in phase II/III clinical trials for use against HAT(3,69). 
The chemical structure of the drug can be seen in fig. 
17(69). It belongs to the nitroimidazole group of drugs 
which in turn belong to the nitroheterocyclic family of 
drugs. Nitrofurans such as nifurtimox belong to the 
nitrohetrocyclic group of drugs as well. Nitroheterocyclic 
drugs all have the same general mode of action(70). In fact, 
it was the success reports of nifurtimox used in combination with eflornithine which led to a 
renewed interest in nitro-based drugs as treatment for infectious diseases(71). This resulted in 
the rediscovery of Fexinidazole and its efficacy in treating HAT by the Drugs for Neglected 
Diseases initiative (DNDi)(69). The drug was actually first synthesized in 1978 and showed 
promise, along with its primary metabolites (shown in fig. 17), as treatment against organisms 
Figure 13. Chemical structures of 
fexinidazole and its primary metabolites 
(70). 
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such as Trypanosoma cruzi and Entamoeba histolytica(72). However, development of the drug 
was not followed up after preclinical studies. DNDi rediscovered it while searching for old and 
new imidazoles with activity against T.brucei (72). Pharmacological assessment of fexinidazole 
in mouse models showed that the drug is effective in treating both the haemolymphatic and 
meningo-encephalitic stages of sleeping sickness. Additionally, in vivo and in vitro studies have 
demonstrated that it exhibits activity against both T.brucei gambiense and T.b rhodesiense(73). 
Therefore, Fexinidazole has shown promise as the ideal drug to be used against HAT.  
Combination therapy 
 The use of NECT against HAT and its breakthrough in the treatment of the disease 
exhibit the advantage of combination therapies. Drug combination therapies often used to 
result in increased efficacy, decreased toxicity, and delayed onset of drug resistance in the 
target parasites(57). Emergence of parasitic resistance is one of the major drawbacks of long-
term monotherapies, hence why combination therapies are used(63). The reasoning behind the 
use of combination therapies to combat or decrease potential resistance is that the likelihood 
of parasites developing resistance to two compounds is much lower than the likelihood of 
resistance to just one compound(71). Therefore, for the combination therapy to reduce the 
likelihood of resistance, the two drugs should be chemically unrelated, making cross-resistance 
between the two unlikely(74). If the two drugs are chemically unrelated, then they likely have 
different modes of action and can contribute to the decreased resistance potential. This is 
supported by the demonstration of cross-resistance between nifurtimox and fexinidazole which 
are both nitroheterocyclic drugs(70). The cross-resistance study showed that nifurtimox-
resistant T.brucei cells exhibited relative resistance to fexinidazole as well. This phenomenon 
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was also observed between fexinidazole-resistant trypanosomes and nifurtimox treatment(71). 
However, nifurtimox-resistant cells were still sensitive to pentamidine and eflornithine, both 
chemically unrelated drugs(71). Ideally, partner drugs for new antitrypanosomal drugs should 
be found before widespread clinical use of the new drug. 
 The exact mechanism of action of nitroheterocyclic drugs such as fexinidazole is not 
known(70). However, they are believed to be prodrugs which, when reduced, cause damage to 
DNA, proteins, and lipids(71). They do this by relying on nitroreductase enzymes (NTR) to 
catalyze their reduction, producing cytotoxic species such as the superoxide anion and the 
hydroxyl radical(71,72). This mode of action is different from that of eflornithine which inhibits 
an enzyme involved in polyamine synthesis. Therefore, considering all the information 
presented on the advantage of combination therapies, it is my hypothesis that eflornithine will 
be the ideal partner drug for fexinidazole.  
Proposed experiment 
 Eflornithine’s ability to serve as the partner drug for Fexinidazole will be determined by 
testing the efficacy of the combination therapy against T,brucei in comparison to the efficacy of 
Fexinidazole monotherapy. Before this is done, however, the optimal concentration of 
eflornithine to be used in conjunction of Fexinidazole must be found. In addition, the 
combination therapy will be tested against lab-generated fexinidazole-resistant (FxR) T.brucei 
to determine sensitivity of the trypanosomes to the drug combination. 
Methods and tools 
Cell line and culture condition:  
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The T.b brucei S427 bloodstream form will be used in all experiments. The cells will be 
cultured according to the protocol of Sokolova et al(71). The cells will be cultures at 37°C in 
HMI9-T medium. The medium will be supplemented with 2.5 μg/ml G418 according to the 
protocol. Fexinidazole-resistant (FxR) cells will also be cultured in these conditions. 
 Determination of optimal eflornithine dose in vitro:  
This growth inhibition assay will be done according to the protocol used by Kaiser et 
al(74). Five different concentrations of eflornithine will be used in conjunction with 200mg of 
Fexinidazole. The different combinations will be introduced into 96-well plates along with the 
culture medium. Two additional plates will be used, one with no drugs added and another with 
200mg of Fexinidazole only. The wells will then be inoculated with 2000 trypanosomes. 
Incubation of the cell cultures will be done at 37°C under a humidified 5% CO2 atmosphere for 
70h. Trypanosome growth inhibition caused by the different drug combinations and 
monotherapy will be analyzed using a microplate fluorescence scanner. The eflornithine 
concentration which is most effective in combination with fexinidazole will be used in 
subsequent assays.   
Determination of combination therapy efficacy: 
 This part of the experiment will be done in vivo using three groups of adult NMRI male 
mice which will be fed and kept under standard conditions. Each group will contain ten mice for 
the purpose of this experiment. Infection of the mice with wild type (WT) T.brucei 
trypanosomes will be done by inoculating them (intraperitoneally) with 104 of the parasite in 
0.2mL of HM19-T medium(74). Forty-eight hours post-infection, one group will be injected with 
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Fexinidazole (200mg/kg), one will be injected with the combination of fexinidazole and 
eflornithine, and the last group will be left untreated. This group will serve as the control. The 
treatment will be repeated for three days. Mice will be monitored over a period of thirty days 
both for clinical signs of infection and parasitemia levels. Clinical signs include raised hair coats, 
dullness, excessive sweating and decreased appetite which normally coincide with a peak in 
parasitemic levels(75). Parasitemia levels will be determined using a hemocytometer on wet 
blood smears extracted from the tail. The blood smears will be examined microscopically as 
well.  
Generation of Fexinidazole-resistant (FxR) cells: 
 Fexinidazole-resistant T.brucei  cells will be generated in vitro according to the protocol 
described by Wyllie et al(70). FxR cells will be generated by exposing the parasitic cells to the 
continuous presence of Fexinidazole in culture. The cells will be subcultured in media with drug 
concentration increasing in a step-wise manner starting with a sublethal concentration of 1.0 
μM until they are surviving and growing in 50 μM of Fexinidazole. Cloning of the now resistant 
cells will be done after 140 days of the cells in culture. Cloning will be achieved in the absence 
of Fexinidazole using limited dilution techniques. The cloned cell lines will then be tested for 
resistance to fexinidazole and the cell line displaying the most resistance will be used for 
subsequent experiments.  
Determination of combination therapy efficacy against FxR cells: 
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  This part of the experiment will be set up like the other in vivo study described above. 
However, mice will be inoculated with FxR cells rather than WT cells. Parasitemia levels will also 
be determined the same way.  
Proposed results 
 If eflornithine eventually proves to be the ideal partner for the combination therapy, 
first, one of the three doses of eflornithine tested in conjunction with Fexinidazole will prove to 
be most effective. In other words, the drug combination involving this optimal dose will show a 
faster rate of activity against trypanosomes than the monotherapy and the other drug 
combinations. Once this optimal dose is determined, the efficacy of the monotherapy will then 
be compared to that of the monotherapy in vivo. Decreased parasitemic levels in comparison 
with the monotherapy should also be observed in this experiment. 
 Trypanosome resistance to Fexinidazole will be induced using the experimental protocol 
described above. The resulting T.brucei cell line will then be cloned as described in the 
experimental protocol. The cloned cell line that displays the most resistance to Fexinidazole will 
then be used for further testing. In vivo, this cloned cell line should be more sensitive to the 
eflornithine and Fexinidazole combination therapy than the monotherapy. In other words, 
parasitemic levels in FxR-infected mice should be lower when treated with the combination 
therapy in comparison to the mice treated with the monotherapy. 
 With combination therapies, there are two possible effects that can be observed in the 
results, synergistic or additive. A synergistic effect will yield results showing that the 
combination therapy was more effective, displaying lowered parasitemic levels over a shorter 
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time period than fexinidazole monotherapy. Conversely, an additive effect will yield results 
which show that the combination therapy is not inferior to the monotherapy alone, proving it is 
just as effective as clearing parasitemia as the monotherapy. It is difficult to predict which 
combined effect the two drugs will have when used in combination without the actual 
experiment being carried out. 
Discussion 
 Fexinidazole has proven to be the ideal drug to be used in treating HAT-infected 
patients. Its status as a model HAT drug is due to its observed efficacy in treating both the early 
and late stages of Gambiense as well as Rhodesiense HAT. However, trypanosome resistance to 
the drug seemed to be generated with relative ease in the laboratory in the Sokolova et al. 
study(74). FxR parasites for the experiment in this paper will be generated using Sokolova’s 
techniques as well. Although this resistance was deliberately induced in vitro and is not fully 
predictive of actual human resistance, potential parasitic resistance is still an issue that must be 
taken into account. The use of eflornithine, a chemically unrelated drug to Fexinidazole, as a 
partner drug in a combination therapy is a possible solution to this issue. Depending on the 
results obtained from the experiment, the combination of fexinidazole with eflornithine will, 
hopefully, either have a synergistic toxic effect on the trypanosome cell or an additive one. 
Although the additive toxic effect of eflornithine will not preclude the use of the combination 
therapy, a synergistic effect is preferable as this will contribute even more to the advantage of 
the combination therapy. Additionally, this experiment will be carried out according to FDA 
protocols for product development under the animal rules(76). Therefore, two mice from each 
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group will be sacrificed and necropsied to ensure that the two drugs, when used in conjunction 
with each other, do not have or cause any unforeseen adverse effects and is well-tolerated.  
 Fexinidazole has been effective in treating both the early and late stages of sleeping 
sickness in mice in vivo at 100mg/kg or 200mg/kg depending on the subtype of the disease(74). 
The use of a 200mg/kg dose in the conduction of the proposed experiments is based on this 
finding. However, further testing may prove that the combination therapy works just as well 
with a reduced dose. It is also possible that a higher dose of Fexinidazole will be more effective. 
Although this is unlikely, the 50% lethal dose of Fexinidazole of >10,000 mg/kg means that 
toxicity of this higher dose will be low if present at all. 
 Trypanosoma brucei brucei parasites are going to be used in this study because they are 
bloodstream forms commonly used in experimental models for HAT. Future studies should be 
done with T.b gambiense and T.b rhodesiense trypanosomes to ensure that the combination 
therapy has the same effect as that observed on the bloodstream T.b brucei parasites. These 
future studies should also observe the effect of the combination therapy on both the early and 
late stages of HAT. 
Conclusion 
 It is thought that nitroheterocyclic drugs are particularly vulnerable to the development 
of drug resistance because they rely on only one enzyme for activation(71). According to the 
cross-resistance study from which the experimental protocol for generating FxR cells was 
derived, the ability to generate FxR and NfxR (nifurtimox-resistant) trypanosomes with relative 
ease supports this hypothesis. Therefore, a combination therapy to reduce potential resistance 
T o m a  | 34 
 
to Fexinidazole is imperative as parasitic resistance to the drug will have serious consequences 
on the use of nitroheterocyclic drugs against HAT in the future along with current treatments 
for the disease(71). If the proposed results from this experiment are obtained, then this would 
prove eflornithine’s potential as the ideal partner drug to be used in conjunction with 
Fexinidazole in a combination therapy because it would either have an additive or synergistic 
effect against T.brucei parasites while also reducing potential resistance to the drug. However, 
before the combination therapy can be used clinically, its safety must be established according 
to the preexisting FDA requirements for establishing the safety of new drug and biological 
products(76). 
 There is no prophylactic treatment for sleeping sickness, instead, its control is based 
primarily on chemotherapeutic measures. The discovery of Fexinidazole and its status as a 
potential ideal drug against HAT once it completes clinical trials was a breakthrough in the 
control and management of the disease. It is therefore, likely that the drug will experience long-
term usage in treating sleeping sickness. However, with long-term monotherapies, the potential 
for development of parasitic resistance is more likely and can be countered by using partner 
drugs for a combination therapy. This thesis was designed to show eflornithine’s potential as 
the partner drug for Fexinidazole. If the partnership is shown to be effective, then the 
combination therapy will contribute greatly towards the WHO goal of HAT elimination by 
2020(2). 
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